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Abstract: Rotaviruses (RVs) are important enteric pathogens of newborn humans and animals,
causing diarrhea and in rare cases death, especially in very young individuals. Rotavirus vaccines
presently used are modified live vaccines that lack complete biological safety. Previous work from our
laboratory suggested that vaccines based on in situ produced, non-infectious rotavirus-like particles
(RVLPs) are efficient while being entirely safe. However, using either vaccine, active mucosal
immunization cannot induce protective immunity in newborns due to their immature immune
system. We therefore hypothesized that offspring from vaccinated dams are passively immunized
either by transfer of maternal antibodies during pregnancy or by taking up antibodies from milk.
Using a codon optimized polycistronic gene expression cassette packaged into herpesvirus particles,
the simultaneous expression of the RV capsid genes led to the intracellular formation of RVLPs in
various cell lines. Vaccinated dams developed a strong RV specific IgG antibody response determined
in sera and milk of both mother and pups. Moreover, sera of naïve pups nursed by vaccinated
dams also had RV specific antibodies suggesting a lactogenic transfer of antibodies. Although full
protection of pups was not achieved in this mouse model, our observations are important for the
development of improved vaccines against RV in humans as well as in various animal species.
Keywords: HSV-1 amplicon vector; rotavirus-like particles; lactogenic antibody transfer
1. Introduction
Rotavirus (RV) is an enteric pathogen of humans and other vertebrates. Symptoms of RV infection
include gastroenteritis, leading to dehydrating diarrhea and death in some cases (for reviews see [1,2]).
More than an estimated 700,000 children under the age of five died of diarrhea in 2011. Importantly,
28% of these fatal diarrhea cases were associated with RV [3].
Although there are licensed RV vaccines available, their protective effect against severe RV
induced diarrhea was found to be extremely region specific with a good efficiency in developed
regions (90.6%). By contrast, in other regions, such as in sub-Saharan Africa, protection was only
46.1% [4]. Globally approved vaccines include either live attenuated (Rotarix, RV1; GlaxoSmithKline
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Inc., Rixensart, Belgium) or reassortant RV strains (RotaTeq, RV5; Merck and Co., Inc., Whitehouse
Station, NJ, USA). Hence, both vaccines are based on replicating viral strains and are thus not safe
by nature. A case report from 2010 described the RV transmission from a RotaTeq vaccinated child
to its unvaccinated sibling. This vaccine associated infection resulted in gastroenteritis that required
emergency care. The transmitted RV strain was a reassorted vaccine-derived strain. Reassortment may
have resulted in the recovery of virulence [5]. In addition, both RV vaccines were found to be associated
with a slightly increased risk of intussusception after the primary vaccination [6]. Therefore, it is
necessary to develop more efficient and in particular safer vaccines. Here, we present our findings on
an alternative vaccine approach that ultimately aims to protect children from RV infection-associated
symptoms in their early time of life.
Virus-like-particles (VLPs) are composed of one or several viral capsid proteins that self-assemble
into a spatial conformation that resembles the structure of the original virus. Virus-like-particles
comprise a high density of epitopes on their surface, which can be recognized by antigen presenting
cells (APCs) and thereby stimulate a humoral and cellular immune response through similar pathways
as the complete, pathogenic virus [7]. Virus-like-particles do not contain any genetic material and
thus do not replicate and are therefore considered safe. Vaccines based on purified VLPs, for example
Gardasil (Merck and Co., Inc., Whitehouse Station, NJ, USA) and Cervarix (GlaxoSmithKline, Inc.,
Brentford, UK) for human papilloma virus (HPV) immunization and Recombivax HB against hepatitis
B virus (HBV; Merck and Co., Inc., Whitehouse Station, NJ, USA), are on the market [8].
The mature infectious RV particles are non-enveloped, triple-layered capsids composed of the
structural proteins VP2, forming the inner most shell, VP6 assembling as the middle layer and VP7 as
third and most outer layer that forms a net-like structure adhering to VP6 [1]. For the attachment to the host
cell, the capsids also contain VP4 spikes that protrude through VP7 pores and attach to the VP6 layer.
To produce VLPs of RV, many expression vectors exist and several vaccine candidates have been proven
to be effective against RV induced diarrhea or virus shedding in small animal models. Triple-layered
VLPs containing VP2, VP6 and VP7 [9,10] or double-layered VLPs consisting of VP2 and VP6 are
examples of this approach [11]. Moreover, subunit vaccines produced of VP6 in eukaryotic cells [12,13]
or VP2 and VP6 expressed as soluble proteins in Escherichia coli and assembled into VLPs [14] showed
protection against RV induced disease. However, the assembly of RV structural proteins into rotavirus
like particles (RVLPs) requires the simultaneous expression of several recombinant RV genes in a
single cell followed by multiple purification steps of these RVLPs. These are challenging steps in the
production of a stable, mass-produced vaccine.
To circumvent these problems but maintaining the ease of application and safety, we decided to
trigger the immune response using RVLPs produced within cells of the vaccinee but in the absence of
RV genome synthesis. We used the herpes simplex virus type-1 (HSV-1) amplicon vector to deliver a
DNA cassette with a single polycistronic messenger RNA which contains the coding sequences of the
three capsid proteins VP2, VP6, and VP7, separated by internal ribosome entry sites for the production
of the RVLPs. The HSV-1 amplicon vector system with its high transgenic capacity of up to 150 kb is
safe as the transgenes are unable to replicate [15], but allow delivery of synthetic DNA encoding any
antigen of interest [16]. With this system, the time consuming and complex purification of VLPs is not
required. Herpes simplex virus type-1 amplicon vector transduction triggering RVLP production was
shown in previous studies from our laboratory but VP2 and VP7 were dramatically underrepresented
compared to VP6 [17].
Structural vaccinology approaches involve the engineering of immunogens using a combination
of structural biology and immunology with the idea that the protective antigens are optimized and
simplified for inclusion in vaccine formulations to enhance efficacy, stability and delivery to obtain a
stronger immunogenicity and hence a broader protection. An important goal of structural vaccinology
is the conformational stabilization of an antigen based on its native three-dimensional structure to
induce an efficacious immune response. Based on these principles, we aimed to increase the amounts
of VLP-generating and immunizing proteins synthesized in situ, we chose to alter the sequence of
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viral genes in the amplicon vector and optimized the amino acid sequence to the codon usage of
human cells.
Protection of newborn human and mice against various pathogens is supported by placental
transfer of antibodies from mother to child and, additionally, after birth via the lactogenic route [18–20].
Notably, the number of placental layers between mothers and their fetuses is different for various
mammals, which affects or inhibits the ability to transfer antibodies during pregnancy. The mammals
cluster into three groups, with humans belonging to group 1, where, due to their single layer placenta
type, the major amount of immunoglobulin is transferred to the fetus prior to parturition [21].
In group 2, with mice and dogs as examples, the immunoglobulins are transferred both through
the placental and the lactogenic pathway. The efficiency by which different isotypes of antibodies
are transferred to the milk differs between the individual species. Although being aware of these
differences, it was of interest to observe the general potency of our vaccine type in a mouse model.
We thus studied the kinetics of anti-RV antibody production in the sera of mice as well as in their
milk. Moreover, we tested for prepartum antibody transfer compared to the postpartum transfer
by milk. Finally, we also tested the protective effect of passive antibody transfer in the context of a
challenge infection.
Here, we show that the transduction of cells in vitro with the HSV-1 amplicon vector that delivers
a DNA cassette encoding a single polycistronic messenger RNA, which contains the coding sequences
of the three capsid proteins VP2, VP6, and VP7 triggers the synthesis of all three encoded RV proteins.
Moreover, these proteins assemble into RVLPs within the transduced cells. When administered
intramuscularly, the RV protein encoding HSV-1 amplicon vectors induce a RV specific antibody
response detected in sera as well as in milk of vaccinated dams and in addition in sera of their
unvaccinated offspring nursed by vaccinated animals. Although lactogenic transfer of RV specific
immunoglobulin G (IgG) to the pups of vaccinated dams occurred, full protection of the newborn
against RV induced symptoms was not achieved under the present experimental conditions.
2. Results
2.1. Codon-Optimized Herpes Simplex Virus Type-1 Amplicon Vectors Trigger Synthesis of Rotavirus
Structural Proteins
The HSV-1 amplicon vectors used in this study are shown schematically in Figure 1A.
The sequence for the construction of the synthetic transgene cassettes of sWa[VP2/6/7] and
sWa[VP2/6/7_V5] was derived from the human RV strain Wa, codon-optimized to human gene
codon preference and constructed as described in the Materials and Methods section. The HSV-1
amplicon vector encoding the green fluorescent protein (GFP) was used as a control vector.
Synthesis of the RV proteins mediated by the synthetic HSV-1 amplicon vectors sWa[VP2/6/7] and
sWa[VP2/6/7_V5] was confirmed by Western blot analysis of total cell lysates following transduction
of cells. All three RV proteins VP2, VP6 and VP7 were synthesized in human and non-human cells
shown in Figure 1B for the human hepatocellular cells HepG2. Furthermore, the V5 tagged VP7
(VP7_V5) was detected using the V5 antibody in cells transduced with sWa[VP2/6/7_V5] (Figure 1B,
middle panel).
The design of both synthetic HSV-1 amplicon vectors sWa[VP2/6/7] and sWa[VP2/6/7_V5] was
based on the vector RRV[VP7/6/2] with the aim to improve transcription/translation of the transgene
cassette through codon-optimization to human codon usage. Through optimization of the codon usage,
the codon adaption index (CAI) increased from 0.605 to 0.895 for human and from 0.606 to 0.892 for
mouse. Indeed, the codon-optimized vector sWa[VP2/6/7] induced an enhanced protein synthesis in
human cells over the non-codon-optimized vector RRV[VP7/6/2] (Figure 1C, left panel). This effect
was not observed in the murine hepatoma cell line Hepa1-6 (Figure 1C, right panel) even though the
CAIs for the codon usage of humans and mice were very similar.
Next, the subcellular distribution of the different RV structural proteins in HSV-1 vector transduced
Vero2-2 cells was examined by confocal laser scanning microscopy and specific antibodies (Figure 1D).
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The VP2 signal was detected as punctate pattern distributed throughout the cytoplasm and VP6
expression appeared as discrete punctate and circular structures in the cytoplasm. V5-tagged VP7
was detected in the cytoplasm as dot structures, some forming aggregates. When compared to the
concanavalin A (ConA) staining of the endoplasmic reticulum (ER) membranes, VP7 was localized at
the ER as previously described [15,21].
These results demonstrated that all three RV structural proteins VP2, VP6, and VP7 were synthesized
from the newly designed HSV-1 cassettes in human and non-human cells and the codon-optimization
led to an increased quantity of generated RV proteins in human cells.
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Figure 1. Rotavirus (RV) protein synthesis upon herpes simplex virus type-1 (HSV-1) amplicon vector 
transduction. (A) Schematic representation of the polycistronic gene expression cassettes packaged 
into herpesvirus amplicon particles. Herpes simplex virus type-1 amplicon particles deliver a DNA 
cassette comprising a single polycistronic messenger RNA containing the coding sequences of three 
RV capsid proteins VP2, VP6 and VP7 separated by internal ribosome entry sites (IRES) and 
controlled by the HSV-1 immediate early (IE) 4/5 promoter. The HSV-1 origin of DNA replication 
(oriS) and packaging/cleavage signal (pac) as well as the SV40 polyadenylation sequence (polyA) are 
indicated. The synthetic RV cassettes derived from the human Wa strain were adjusted to human 
codon usage (synthetic strain Wa, sWa). The RRV[VP7/6/2] was derived from the rhesus strain RRV 
and encodes, in addition to the RV proteins, for the enhanced green fluorescent protein (EGFP) as 
reporter gene. The sWa[VP2/6/7_V5] amplicon vector harbors a C-terminal V5 tag at VP7. The GFP 
amplicon vector encoding EGFP was used as control vector. (B) Rotavirus gene expression from 
codon optimized transgene cassettes. HepG2 cells were transduced with the indicated amplicon 
vectors (multiplicity of infection, MOI 2) or non-transduced (mock), and total cell lysates were 
harvested at 24 h post-transduction (hpt). Transgene expression was analyzed by Western blotting 
using the polyclonal anti-RV antibody to detect RV proteins (upper panel), the anti-V5 antibody for 
detection of the V5 tagged VP7 protein (middle panel), or the anti-actin and anti-GFP antibodies 
(lower panel). Detection of actin served as loading control. The predicted migration lengths of VP2 
(104 kDa), VP6 (45 kDa), VP7 (37 kDa), VP7_V5 (42 kDa), actin (42 kDa) and GFP (27 kDa) are 
indicated on the left with arrows. The positions of the molecular weight markers are indicated on the 
right in kDa. (C) Analysis of protein synthesis in human and mouse cells. Human HepG2 or mouse 
Hepa 1-6 cells were transduced either with sWa[VP2/6/7], RRV[VP7/6/2] or GFP HSV-1 amplicon 
vectors (MOI 2) or non-transduced (mock) and total cell lysates were harvested 24 hpt. Transgene 
expression was analyzed using the polyclonal anti-RV antibody for detection of RV proteins (upper 
panels), the anti-actin antibody (middle panels) or the anti-GFP antibody (lower panels). Detection of 
actin served as loading control. The predicted migration lengths of the individual proteins are 
indicated on the left and the positions of the molecular weight markers are shown in kDa on the right. 
(D) Intracellular distribution of HSV-1 amplicon vector encoded RV proteins. Vero2-2 cells were 
transduced with the amplicon vector sWa[VP2/6/7_V5] at an MOI of 1 and analyzed by immune 
fluorescence 24 hpt with a Leica SP8 confocal laser scanning microscope. The RV proteins were 
stained using the following antibodies: anti-VP2 antibody directly labeled with Zenon Alexa-Fluor 
594 (red), anti-VP6 and the anti-mouse Alexa-Fluor 633 (cyan), anti-V5 directly labeled with 
fluorescein isothiocyanate (FITC) for the V5-tagged VP7 (green). The endoplasmic reticulum (ER) was 
stained using the Alexa-Fluor 405 conjugated lectin concanavalin A (ConA) (grey). 
2.2. Ultrastructural Analysis of Intracellular Rotavirus-Like Particles 
In a next step, HepG2 cells were transduced with sWa[VP2/6/7] and ultrathin sections were 
prepared for transmission electron microscopy (TEM) (Figure 2A,B). The structures detected 
resembled RV particles or viroplasms [22]. To prove that these structures represented accumulated 
RV proteins, correlative light and electron microscopy [23] was done (Figure 2C,D). The ultrathin 
sections of vector-transduced cells were labeled as indicated in the Materials and Methods section 
and imaged with a fluorescence microscope. The resulting micrograph was used as a map to record 
the same area in the electron microscope (EM). Figure 2C shows an overlay of the fluorescent and the 
EM images and Figure 2D is an enlargement of the area of interest recorded by the EM, focusing on 
the highly RV-antibody-positive marked and electron-dense regions. Such electron-dense and 
antibody-positive regions showed regularly shaped circular structures that formed aggregates or 
clusters resembling virus particles.  
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Figure 1. Rotavirus (RV) protein synthesis upon herpes simplex virus type-1 (HSV-1) amplicon
vector transduction. (A) Schematic representation of the polycistronic gene expression cassettes
packaged into herpesvirus amplicon particles. Herpes simplex virus type-1 amplicon particles deliver
a DNA cassette comprising a single polycistronic messenger RNA containing the coding sequences
of three RV capsid proteins VP2, VP6 and VP7 separated by internal ribosome entry sites (IRES) and
controlled by the HSV-1 immediate early (IE) 4/5 promoter. The HSV-1 origin of DNA replication
(oriS) and packaging/cleavage signal (pac) as well as the SV40 polyadenylation sequence (polyA) are
indicated. The synthetic RV cassettes derived from the human Wa strain were adjusted to human
codon usage (synthetic strain Wa, sWa). The RRV[VP7/6/2] was derived from the rhesus strain RRV
and encodes, in addition to the RV proteins, for the enhanced green fluorescent protein (EGFP) as
reporter gene. The sWa[VP2/6/7_V5] amplicon vector harbors a C-terminal V5 tag at VP7. The GFP
amplicon vector encoding EGFP was used as control vector; (B) Rotavirus gene expression from codon
optimized transgene cassettes. HepG2 cells were transduced with the indicated amplicon vectors
(multiplicity of infection, MOI 2) or non-transduced (mock), and total cell lysates were harvested at 24 h
post-transduction (hpt). Transgene expression was analyzed by Western blotting using the polyclonal
anti-RV antibody to detect RV proteins (upper panel), the anti-V5 antibody for detection of the V5
tagged VP7 protein (middle panel), or the anti-actin and anti-GFP antibodies (lower panel). Detection
of actin served as loading control. The predicted migration lengths of VP2 (104 kDa), VP6 (45 kDa),
VP7 (37 kDa), VP7_V5 (42 kDa), actin (42 kDa) and GFP (27 kDa) are indicated on the left with arrows.
The positions of the molecular weight markers are indicated on the right in kDa; (C) Analysis of protein
synthesis in human and mouse cells. Human HepG2 or mouse Hepa 1-6 cells were transduced either
with sWa[VP2/6/7], RRV[VP7/6/2] or GFP HSV-1 amplicon vectors (MOI 2) or non-transduced (mock)
and total cell lysates were harvested 24 hpt. Transgene expression was analyzed using the polyclonal
anti-RV antibody for detection of RV proteins (upper panels), the anti-actin antibody (middle panels)
or the anti-GFP antibody (lower panels). Detection of actin served as loading control. The predicted
migration lengths of the individual proteins are indicated on the left and the positions of the molecular
weight markers are shown in kDa on the right; (D) Intracellular distribution of HSV-1 amplicon vector
encoded RV proteins. Vero2-2 cells were transduced with the amplicon vector sWa[VP2/6/7_V5] at
an MOI of 1 and analyzed by immune fluorescence 24 hpt with a Leica SP8 confocal laser scanning
microscope. The RV proteins were stained using the following antibodies: anti-VP2 antibody directly
labeled with Zenon Alexa-Fluor 594 (red), anti-VP6 and the anti-mouse Alexa-Fluor 633 (cyan), anti-V5
directly labeled with fluorescein isothiocyanate (FITC) for the V5-tagged VP7 (green). The endoplasmic
reticulum (ER) was stained using the Alexa-Fluor 405 conjugated lectin concanavalin A (ConA) (grey).
2.2. Ultrastructural Analysis of Intracellular Rotavirus-Like Particles
In a next step, HepG2 cells were transduced with sWa[VP2/6/7] and ultrathin sections were
prepared for transmission electron microscopy (TEM) (Figure 2A,B). The structures detected resembled
RV particles or viroplasms [22]. To prove that these structures represented accumulated RV proteins,
correlative light and electron microscopy [23] was done (Figure 2C,D). The ultrathin sections of
vector-transduced cells were labeled as indicated in the Materials and Methods section and imaged
with a fluorescence microscope. The resulting micrograph was used as a map to record the same area
in the electron microscope (EM). Figure 2C shows an overlay of the fluorescent and the EM images
and Figure 2D is an enlargement of the area of interest recorded by the EM, focusing on the highly
RV-antibody-positive marked and electron-dense regions. Such electron-dense and antibody-positive
regions showed regularly shaped circular structures that formed aggregates or clusters resembling
virus particles.
We conclude that the observed circular structures represent indeed RVLPs formed in the cytoplasm
of HSV-1 transduced cells resembling viroplasms found in RV-infected cells.
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opened with the software Maps on the scanning electron microscope (SEM) computer, aligned with 
the secondary electron image and a tileset of images was recorded using the high-angle annular dark-
field detector. (C) Overlay of the fluorescent and the electron microscope image of a stitched tileset of 
images covering the entire cell of interest. On the fluorescence micrograph, 4′,6-diamidino-2-
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Figure 2. Ultrastructural analysis of transduced cells using electron microscopy. (A,B) Transmission
electron micrographs of RVLP formation in the cytoplasm of vector-transduced cells. HepG2 cells
were transduced (multiplicity of infection, MOI 5) with the HSV-1 amplicon vector sWa[VP2/6/7].
The cells were harvested 24 hpt from monolayers, processed as described in the material section and
analyzed in a transmission electron microscope equipped with a charge-coupled device (CCD) camera;
(B) Enlargement of the region marked in (A) showed clusters of regular circular structures found in the
cytoplasm of the transduced cell. Scale bar: (A) 2 µm; (B) 0.5 µm. (C,D) Correlative light and electron
microscopy. HepG2 cells were transduced (MOI 5) with the HSV-1 amplicon vector sWa[VP2/6/7_V5].
The cells were harvested 24 hpt from monolayers by pelleting and fixation with 4% formaldehyde
and embedded in LR White. Ultrathin sections were directly collected on grids, prepared for immune
fluorescence and images were taken using a fluorescence microscope. Thereafter, the same grids were
further processed for electron microscopy. The fluorescent image was opened with the software Maps
on the scanning electron microscope (SEM) computer, aligned with the secondary electron image and
a tileset of images was recorded using the high-angle annular dark-field detector; (C) Overlay of the
fluorescent and the electron microscope image of a stitched tileset of images covering the entire cell
of interest. On the fluorescence micrograph, 4′,6-diamidino-2-phenylindole (DAPI) was used to stain
the nuclei (blue), and RV proteins were stained using the anti-RV serum and the secondary antibody
conjugated with Alexa-Fluor 488 (green); (D) Enlargement of the area of interest of the stitched tileset
showing the highly RV-positive-marked electron-dense region marked in (C). Scale bar: (C,D) 1 µm.
2.3. Rotavirus Specific Antibody Response Induced by Immunization with sWa[VP2/6/7]
We injected female mice with 106 transducing units (TU) per dose intramuscularly (i.m.) in
a prime-boost regimen with sWa[VP2/6/7] or the GFP encoding amplicon vector as control. Five
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days after the first immunization, males were added to the females for mating (Figure 3A). Nineteen
days after the prime immunization, dams were boosted. Blood and milk samples from dams were
collected after parturition and tested for RV specific IgG antibodies using a RV (strain Wa) specific
enzyme-linked immunosorbent assay (ELISA). Rotavirus specific IgG antibodies were found in sera
of all sWa[VP2/6/7] immunized mice that differed significantly from the sera of GFP immunized
control mice (Figure 3B). The data used to generate the plot in 3B as well as the number of animals
included in this study and p-values are provided in the Appendix A as Table A1. Mice immunized
with sWa[VP2/6/7] showed a relative RV-specific IgG (rIgG) level of 54.85% at day 10 post-booster
immunization (dpb), which decreased to 37.89% rIgG at 14 dpb and then decreased to 23.78% rIgG at
20 dpb. Relative IgG of pre-immune sera from animals of both groups was close to 0 (rIgG value of
1.45% for animals of the sWa[VP2/6/7] group and 0.69% in animals of the GFP group). The rIgG levels
of the GFP vector immunized control group were low over the entire duration of the experiments
with 2.15% at 10 dpb, 1.38% at 14 dpb and 1.92% at 20 dpb. This indicates that a RV specific antibody
response was triggered upon sWa[VP2/6/7] vector immunization.
Rotavirus-specific IgG in milk of sWa[VP2/6/7] immunized mice paralleled the titer in their sera
(Figure 3C,D; for details see Appendix A in Tables A2 and A3). On the day of parturition (day 0), levels
in milk from sWa[VP2/6/7] immunized animals was found to be at 46.64%, increased to 57.26% on
day 3 and slightly decreased to 51.83% rIgG on day 6 after parturition. In contrast, GFP immunized
animals showed background IgG in milk with 1.24% on day 0, 2.25% on day 3 and 1.97% on day 6 after
parturition. Levels of RV-specific IgA antibody in all of the milk or sera samples tested were below
the sensitivity of the ELISA used. Importantly, titer of sera and milk antibodies were similar between
delivery and the first seven days (Figure 3C,D, Tables A2 and A3).
We further analyzed the isotypes of RV specific IgG raised upon sWa[VP2/6/7] immunization
and GFP controls (Table A4). All sWa[VP2/6/7] immunized dams showed higher levels of IgG2a
when compared to IgG1 (Table A5). Sera of their offspring had comparable ratios of IgG1/IgG2a
as the according mothers (Table A5) indicating a type 1 T helper (Th1) immune response induced
by vaccination.
In a next experiment dams were immunized in a prime-boost regimen with either sWa[VP2/6/7]
amplicon or as control GFP amplicon or Hanks’ balanced salt solution (HBSS) (Figure 3A;
Tables A6 and A7 for milk and serum rIgG levels of dams used for this experiment), but pups
were swapped after birth as shown in Figure 3E. A similar RV specific IgG titer was found in terminal
sera of pups from sWa[VP2/6/7] immunized dams as in sera from pups nursed from HBSS control
injected dams (Figure 3E, group A, B). The RV specific IgG of the sWa[VP2/6/7] immunized dams was
thus passed to their offspring or the nursed control pups by the lactogenic route. We also exchanged
the offspring from sWa[VP2/6/7] immunized dams with the offspring of HBSS injected control dams
immediately after birth. Because of the terminal exsanguination, only the remaining maternal antibody
titer of the pups after six days following the transfer to the control dam could be analyzed (Figure 3E,
group “C”). This antibody titer was still elevated compared to the controls (Figure 3E, group “D”).
All data to generate the plot in Figure 3E and the number of included animals for this experiment are
shown in Table A8 in the Appendix A. Table A9 in the Appendix A shows p-values between all groups
in Figure 3E.
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Figure 3. Immune response in mice upon immunization with the vaccine vector sWa[VP2/6/7].
(A) Schematically represented in vivo studies as timeline. Before the immunization of female BALB/c
mice a blood sample was collected from each animal. Five days after intra muscular (i.m.) injection
of the prime dose, a male was added for mating. Before booster immunization, blood samples were
taken. For the first set of experiments, mice received a booster immunization at 19 days after prime
dose injection, and, for the second set of experiments, at 20 days after prime dose injection. Blood and
milk samples were taken on a regular basis starting on the day of parturition. (B–D) Rotavirus specific
immunoglobulin G (IgG) serum (B,D) or milk (C) levels of immunized mouse dams determined by
enzyme-linked immunosorbent assay (ELISA). Rotavirus-specific IgG in sera (1:5000 dilution) or milk
(1:500 dilution) of either sWa[VP2/6/7] or GFP amplicon vector immunized animals was measured and
plotted relative to the positive control applied on each ELISA plate that was taken as 100%. As positive
control always the same sera of a RV hyperimmunized mouse from a previous study [17] (diluted
1:5000) was used. Relative IgG values were plotted on the ordinate in relation to the time after booster
immunization in days on the abscissa. Values from naïve sera are plotted on the time point −19 as
these samples were taken before the first immunization (B). In (B), time point 0 indicates relative sera
IgG levels before booster immunization, time point 10 includes values from animals from 9 to 10 days
post-booster immunization (dpb), time point 14 includes samples taken on 13 and 14 dpb and time
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point 20 from 20 to 21 dpb. Standard deviations between the measurements from sera of individual
animals are indicated. In (C,D) time point 0 indicates values from milk (C) or serum (D) samples
taken on the day of parturition, time point 3 includes all milk samples from three or four days after
parturition and time point 6 includes all samples collected six or seven days post-delivery. Standard
deviations between measurements from milk of individual animals are indicated. p-values between
the sWa[VP2/6/7] and GFP immunized groups are indicated: *, p < 0.05; **, p < 0.01; ***, p < 0.001.
(E) Rotavirus-specific IgG levels in pup sera determined by ELISA. Rotavirus-specific IgG in terminal
sera from the offspring of either sWa[VP2/6/7] or GFP amplicon vector immunized dams or Hanks'
balanced salt solution (HBSS) injected control dams was plotted in relation to the positive control (set
as 100%). In group A, offspring was born and raised by sWa[VP2/6/7] immunized dams. In group B,
offspring was born from HBSS injected dams but raised by sWa[VP2/6/7] immunized dams. Group C
includes offspring born from sWa[VP2/6/7] immunized dams and raised by HBSS injected control
dams. Group D includes offspring born and raised by HBSS-injected control animals. Group E includes
offspring born and raised by GFP vector immunized dams. Here, dams obtained the booster dose
20 days after prime immunization. The standard deviation of each group is indicated. p-values of A
versus C, D or E or B versus C, D or E are indicated: ***, p < 0.001.
We conclude, that RV specific IgG antibody transfer via the placental route occurred. Moreover,
the level of antibody had to be maintained by the lactogenic route by immunized dams or substituted
for naïve pups by milk from immunized dams (Figure 3E). In conclusion, we were able to show that
injection of the sWa[VP2/6/7] amplicon vector raises a RV specific immune response, detected as IgG
in sera as well as in milk of immunized animals and that this response is passed to the offspring via
both the placental and the lactogenic route.
2.4. Protective Effect of Maternal Antibodies against Rotavirus Challenge
We further tested if the vaccine-induced immune response in the suckling mice was sufficient
to protect them from the symptoms of RV infection. Therefore, we challenged the pups of all groups
(either swapped or non-swapped) with oral gavage of mouse RV—strain EDIM, 10× diarrhea dose
50 (DD50)—at two to five days after birth. All pups developed diarrhea within comparable periods of
incubation time. Thus, the immune response raised was not sufficient to protect the suckling mice
from RV induced symptoms in our experimental settings.
It has been reported that RV can become systemic leaving the intestinal route and emerging into
the blood [24,25]. As the strain EDIM cannot be propagated in vitro [26], the viral load in the sera of
pups was analyzed using a RV specific quantitative real-time polymerase chain reaction (RT-qPCR).
The first set of experiments showed promising results indicating that pups from vaccinated dams had
lowest DD50 (DD50/mL) titers whereas pups swapped had 20–50 times higher DD50/mL values that
reflected the antibody titer (Table A10). Subsequent experiments indicated variables due to the age
of the pups at the time of challenge and thus possible developmental stage of immune maturation,
weight of the pups and limitation of sera collection due to the need to kill the experimental animals
(Table A11). We concluded that it was ethically questionable to control all these variables by selecting
a multitude of animals in order to further standardize immunization including controls, birth date,
size of the litter and body weight of the pups for the various swap experiments.
2.5. Serum Antibodies Raised in Vaccinated Dams were Specific for Rotavirus Proteins VP2 and VP6
During our challenge experiments, protection against an oral RV challenge of the suckling
mice was not achieved. In a next step, we analyzed the specificity of the RV antibodies in sera of
vaccinated dams. Our immunization vector sWa[VP2/6/7] comprised three RV antigens, the main
structural proteins VP2, VP6 and VP7. We thus expected antibodies against all three RV antigens in the
immunized animals. To test this, immune fluorescence was performed using the sera from vaccinated
mice and appropriate controls (Figure 4). To generate each antigen, Vero2-2 cells were transduced
with amplicon vectors encoding each of the single RV protein or GFP sera of dams vaccinated with
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sWa[VP2/6/7] bound VP2 and VP6, but not VP7 (Figure 4, first row). This was true for all mice of
this group. Sera of dams vaccinated with the control vector only expressing GFP and of HBSS control
dams did not recognize any of the RV proteins specifically (Figure 4, middle rows), although some
very minor unspecific background staining was seen occasionally. In summary, only antibodies against
the RV VP2 and the VP6 proteins were detected in sera of the sWa[VP2/6/7] vaccinated dams.
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Figure 4. Screening of mice sera using immune fluorescence show VP2- and VP6-specific antibodies in
the sera of vaccinated dams. Vero2-2 cells tra sduced (MOI 1) with the cor esponding monocistronic
amplicon vectors encoding individual RV proteins VP2, VP6 or VP7 were stained 24 hpt by immune
fluorescence. The sera of vaccinated dams served as primary antibodies (diluted 1:100) and were
detected by the secondary antibody anti-mouse conjugated with Alexa-Fluor 594 (red). GFP fluorescence
(green) expressed as reporter gene from each amplicon vector served to identify transduced cells, DAPI
was used to stain the nuclei (blue). Polyclonal anti-RV serum served as positive control.
2.6. Composition of Rotavirus-Like Particles Produced in Herpes Simplex Virus Type-1 Transduced Cells
Previous work showed that VP7 might pl y a k y rol in pas ive protection of pups from
RV-induced diarrhea [27]. Based on the results from the i mune fluorescence analysis of the mice
sera, we were able to raise VP2- and VP6-specific antibodies in the blood of sWa[VP2/6/7] vaccinated
dams, but no VP7-specific antibodies. The use of HSV-1 amplicon vectors to launch the in situ
production of RVLPs provides the ad ntage that s opposed to injection of urified VLPs, the delivery
of VLP encoding genes into host cells results in the intracellular production of antigens. In our case,
we expected the formation of triple-layered RVLPs. Therefore, we further characterized the nature of
our antigen used for vaccination. In a first step, RVLPs formed upon transduction of sWa[VP2/6/7]
gene expression cassettes was analyzed using electron microscopy (Figure 5A,B) and in a second step,
the composition of purified particles was examined using Western blot analysis (Figure 5C). Negative
staining transmission electron microscopy of the purified cell lysates from sWa[VP2/6/7] transduced
cells showed that the synthesized RV structural proteins assembled into RVLPs similar in size and
structure to wild-type RV particles [28]. Further immunogold labeling of these RVLPs using the rabbit
polyclonal anti-RV serum and a secondary antibody conjugated to gold particles confirmed the VLP’s
identity as RV-like.
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Figure 5. Analysis of rotavirus-like particles (RVLPs) produced in HSV-1 amplicon transduced cells.
(A,B) electron micrographs of HSV-1 amplicon vector encoded RVLPs. HepG2 cells were infected
with the polycistroni HSV-1 amplicon vector sWa[V 6/7] and two days after transduction, RVLPs
were purifi d over a sucro e cushion a d the con trated particles were anal zed by tra smission
electron microscopy. (A) Negative staining of RVLPs from HepG2 cells transduced with sWa[VP2/6/7].
(B) Immunogold staining of the same sample of RVLPs as in (A) using a polyclonal anti-RV serum
as primary antibody and a secondary antibody coupled to 12 nm colloidal gold particles. Scale bar:
100 nm (A,B). (C) Double-layered purified RVLPs and remaining RV proteins in he cell pellet. Vero2-2
cells were transduced with the indicated HSV-1 amplicon vectors (MOI 2) or non-transduced (mock).
Cells were harvested 48 hpt and RVLPs were purified and concentrated from the supernatant over a
sucrose cushion. The concentrated RVLPs (purified RVLPs, left panel) and the RV proteins remaining
in the cell pellet obtained during RVLP harvesting (remaining pellet, right pa el) was analyzed by
Western blot ing using a polyclon l anti-RV antibody for detection of RV ro eins or the monoclonal
anti-V5 antibody to detect V5 tagged VP7. In the left panel, whole cell lysate of sWa[VP2/6/7_V5]
transduced (MOI 2) Vero2-2 cells was taken as positive control. The predicted migration lengths of the
RV proteins are indicated on the left with an arrow and the positions of the molecular weight markers
are indicated on the right in kDa.
To analyze the composition of the isolated RVLPs, Western blot analysis of the purified RVLPs
was performed (Figure 5C). This indicated that the observed RVLPs consisted predominantly of the
two inner layers VP2 and VP6 (Figure 5C, left panel), whereas the outer layer protein VP7 remained in
the cell debris pellet obtained during the purification of the RVLPs (Figure 5C, right panel). Moreover,
VP7 is a transmembrane glycoprotein localized at the ER [29] and seemed to localize with the ER
membranes (Figure 1D) even though VP2 and VP6 were co-expressed. In summary, even though VP7
was abundantly present in transduced cells (Figure 1B,C), it was hardly incorporated into the isolated
RVLPs leading to the conclusion that in our system double-layered RVLPs were preferentially formed.
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3. Discussion
The salient new findings in our study include: (1) transduction of cells with our HSV-1 amplicon
vector delivering a DNA cassette encoding a single polycistronic messenger RNA, comprising the
codon-optimized sequences of the three RV capsid proteins VP2, VP6, and VP7, triggered the synthesis
of all three encoded RV proteins; (2) cell-type dependent increase of the desired protein synthesis due to
codon-optimization of the capsid protein coding sequences in the vector; (3) assembly of VP2 and VP6
into double-layered virus-like particles, while VP7 was synthesized in the same cell but, apparently,
excluded from particle formation; (4) intramuscular inoculation of these amplicon particles resulted
in the production of RV-specific antibodies against VP2 and VP6 but, interestingly, not VP7; (5) these
antibodies were transferred to mouse progeny via the uterine and lactogenic pathway; and (6) despite
efficient antibody transfer to offspring, clinical protection against diarrhea upon experimental infection
of the pups with a heterologous, mouse-specific RV was not achieved.
Purification and propagation of RV from clinical fecal specimen in cell culture is difficult and
adaptation to growth in continuous cell lines at high titers usually requires multiple rounds of
passaging in primary cells [30]. Consequently, the results of adaptation usually include alterations in
the amino acid sequences of the proteins of immunogenic interest. We solved this problem by using a
synthetic and codon-optimized DNA cassette, which maintained the original (RV strain Wa, Dhaka
isolate) amino acid sequences of the three major capsid proteins VP2, VP6, and VP7. The particular
strengths of this approach are three-fold: (1) the vaccine can easily be adjusted to the circulating RV
strain, since only the packaged DNA sequence needs to be modified; (2) HSV-1 amplicon vectors have
a high transgene capacity (up to 150 kb) that ensures that multiple copies of the RV protein encoding
genes are delivered and thereby trigger a high amount of protein synthesis; and (3) VLP purification,
which is very expensive and time consuming, can be omitted because VLPs are being formed in situ.
A rationale of structural vaccinology is to maintain the native three-dimensional structure
and to stabilize the conformation of antigens to induce an efficacious immune response. We and
others [14,17,27,31] reported that assembly of structural proteins into VLPs might be crucial for
protection against RV infections. The viral structure is assembled by several proteins on the VLP
surface mimicking the native virions and allowing crucial overlapping epitopes to be recognized by
antibodies that would not be possible by the use of single individual subunits as antigens. Adopting
these principles, we propose that the structural aspect of RVLPs is important for RV specific generation
of protective antibodies. Based on electron microscopic analysis, the RVLPs produced in vitro were
highly analogous to native RV particles. However, further analysis revealed that cell culture purified
RVLPs were predominantly composed of VP2 and VP6 but excluded VP7 (Figure 5C). As known
from literature [1,32], and shown by our data of the intracellular localization of the synthetized
proteins (Figure 1D), VP7 associates with the membranes of the ER, whereas VP2 and VP6 form
punctate structures within the cytoplasm but do not co-localize with the ER membranes. It is not fully
understood how triple-layered particles (TLP) can form under these conditions. However, Coste et al.
were able to purify TLPs following co-infection of insect cells with three different baculoviruses [27]
(i.e., one for the expression of each of the three capsid proteins, VP2, VP6, and VP7).
In contrast to these findings and upon synthesis in mammalian cells, VP7 was abundantly
synthesized but did not co-purify with the VLPs. Instead, upon VLP purification, VP7 remained in
the pellet, together with the cellular debris. Even more surprisingly, antibodies against VP7 were not
induced under these circumstances. Consequently, it might be that the requirements for TLP formation
are different for insect cells and mammalian cells. Indeed, according to others, co-expression of NSP4
and/or VP4 together with the three capsid proteins may play a pivotal role in the assembly of the third
layer [1]. A better understanding of the RV assembly process is needed to solve the problem of VP7
incorporation into VLPs in the future.
Protection against RV infection in adult mice can be measured by reduction of fecal virus shedding
after oral challenge (adult mouse model). However, in all species, including humans and mice,
RV infection in adults is usually asymptomatic and does not cause diarrhea. Similar to human
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babies and in contrast to adult humans and mice, newborn mice develop severe diarrhea upon RV
infection, particularly during the first 14 days of their life [33]. However, the immune system of
newborns is not fully mature at this stage. Thus, immunization of mothers, resulting in the protective
transfer of their antibody repertoire to the offspring, represents an important alternative that can also
be mimicked in the mouse model. Indeed, protection against RV diarrhea by passive maternal
transfer of antibodies has been reported (mouse maternal antibody model) using live-rotavirus
vaccines [34], recombinant adenovirus expressing VP7 [35], recombinant VP6 and VP8 proteins
expressed in E. coli [36], VLPs assembled in insect cells [27] or capsid proteins VP2 and VP6 expressed
in E. coli and assembled into VLPs post-purification [14].
It is widely accepted that the B-cell arm of the immune response plays a major role in controlling
RV infection. Observations are reported not only from mouse experiments but also from clinical studies
in piglets and children [37–39]. However, the mechanisms by which antibody producing cells precisely
act against RV are unclear and therefore extensively discussed in the field. It is important to note that
the amplicon vector induced a Th1 type of immune response with an increased level of IgG2a over
IgG1 (Tables A4 and A5) believed to be effective for the control of viral infection. This Th1 response
might be an indication that our system would be able to induce mucosal IgA in humans.
In the adult mouse model, fecal IgA antibodies against VP6 have been the main correlate for
protection against RV infection and it has been suggested that VP6 specific antibodies are taken up
by the polymeric Ig receptor of the infected enterocyte neutralizing RV intracellularly [40]. However,
the passive transfer of VP6-specific antibodies to newborns was not sufficient to protect against
diarrhea [27,31,41]. Coste et al. demonstrated that nasal immunization of mice with purified TLPs
assembled in insect cells and comprising VP2, VP6, and VP7 triggered high milk and serum antibody
titers. Furthermore, milk but not serum antibodies were associated to the protection of suckling mice
and that antibodies to VP7 played a crucial role [27].
Having the same antigens (VP2, VP6, and VP7) included in our approach and having shown that
all three proteins were being synthesized in transduced cells, we were confident to achieve similar
results in a protection study as Coste et al. [27], though with IgG and upon in situ synthesis of the
viral proteins instead of immunizing with purified VLPs. Indeed, our vaccinated mice produced
high anti RV IgG antibody titers, both in serum and in milk, and they transferred these antibodies to
their offspring. However, we were unable to detect any RV specific IgA antibodies in the vaccinated
mice. Consequently, a clear protection against diarrhea was not achieved. This was in agreement with
previous studies [34,36], which reported that protection from rotavirus diarrhea relied on the lactogenic
transfer of IgA against VP7 or VP4. Of course, several factors contribute to clinical protection against
RV, including a close match of antibodies against the targeted antigens, the amount and isotype of
antibodies as well as the location, where they should act. In the present case, the transfer of antibodies
from the immunized mothers to their suckling mice seemed efficient. However, at least three factors
might have influenced the protective outcome in a negative way: (1) The stringent stop criteria for the
animal experiments did not allow the examination of the duration and severity of RV symptoms in
offspring in the different experimental groups; (2) The antibody isotype generated upon vaccination
was predominantly IgG, whereas IgA is supposed to provide a better level of protection, particularly
in the gut. On the other hand, one may consider that the maternal antibodies had been recovered
from the gut as a consequence of suckling milk containing these antibodies. Thus, the challenging
virus and the potentially protective antibodies had opportunities to meet and to react in the gut, at
least for a certain amount of time. It was, therefore, surprising to note that no obvious protective
effect could be achieved. Of note, we used heterologous RVLPs based on the human RV strain Wa and
mice were challenged with a heterotypic RV, the murine strain EDIM. Thus, it might be that even if
VP7-specific antibodies were raised, no protection was observed because of the poor cross-reactivity
between the raised antibodies; (3) According to Butler et al. [21], the mammals cluster into three
groups, with respect to lactogenic immunity. Rodents, classified in group 2, show particularly good
absorption of IgG from the gut, which drains the gut from functional antibodies. Humans, classified in
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group 1, absorb only little immunoglobulins from the gut, leaving the antibodies to work where they
are supposed to throughout a RV infection. Pigs, classified in group 3, show extensive absorption of all
classes of immunoglobulins but only for the first 12 h. Afterwards, the milk antibodies are known to
work for several weeks particularly well in the porcine gut. This property is even enhanced by the
ability of the pigs to produce high amounts of IgA in response to vaccination.
We conclude from the reasons stated above that the presently used mouse model may be
suboptimal for testing RV vaccines designed for human use. Two possible future approaches emerge
from these considerations: (1) The vaccine should be tested in pregnant women in order to analyze the
antibody specificities and isotypes in their serum as well as their milk; (2) Pigs or cattle, which also
belong to group 3, might be vaccinated in order to produce decent amounts of IgA against various RV
strains. These IgA may find use in medicine as well as in veterinary medicine.
4. Materials and Methods
4.1. Cells and Viruses
Vero 2-2 (African green monkey kidney epithelium cells, [42]), Hepa 1-6 (mouse epithelial
hepatocytes, ATCC), MA104 (embryonic African green monkey kidney, ATCC) and HepG2 (human
liver hepatocellular cells, ATCC) cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS), 100 units/mL of penicillin G, 100 µg/mL
of streptomycin, 0.25 µg/mL of amphotericin B and for Vero2-2 cells also with 500 µg/mL of G418
(Thermo Fisher Scientific, Waltham, MA, USA). The murine wild type (wt) RV strain EDIM was
obtained from Harry Greenberg (Department of Medicine and Microbiology and Immunology, Stanford
University School of Medicine, Stanford, CA, USA). The titration of wt RV EDIM used to challenge
mice after vaccination was described previously [26]. The human RV strain Wa was obtained from
Catherine Eichwald (University of Zurich, Zurich, Switzerland); it was propagated in MA104 cells as
previously described [43].
4.2. Construction of Herpes Simplex Virus Type-1 Amplicon Plasmids
The sequence for the construction of the synthetic transgene cassettes of sWa[VP2/6/7] and
sWa[VP2/6/7_V5] was derived from the human RV strain Wa (Dhaka isolate) and codon-optimized
to human gene codon preference—verified by Genescript (Piscataway, NJ, USA) and synthesized by
Biomatik (Cambridge, Ontario, Canada)—and predicted splice sites were removed [44]. The codon
adaption index [45] was calculated using The European Molecular Biology Open Software Suite
(EMBOSS) [46]. Herpes simplex virus type-1 amplicon plasmids were cloned using Gateway
technology (Thermo Fisher Scientific, Waltham, MA, USA). The attB flanked synthetic gene expression
cassettes (sWaRV) encoding the RV proteins VP2, VP6 and VP7, separated by internal ribosome entry
sites (IRES) either with or without stop codon at the 5′ end were generated by Biomatik. The Gateway
B/P recombination between the attB flanked sWaRV cassette and the attP containing donor vector
pDONR221 led to two entry plasmids containing the sWaRV gene expression cassette flanked by attL
sites either with (pE_sWaRV_STOP) or without stop codon (pE_sWaRV). The amplicon plasmid used
to produce sWa[VP2/6/7] vector stocks was generated by the Gateway L/R recombination between
the attL sites containing entry vector pE_sWaRV_STOP and the attR sites containing destination
vector pHSV-EYFP-RfC_C.1. For production of sWa[VP2/6/7_V5] amplicon vector stocks, pE_sWaRV
was recombined with the destination vector pHSV-V5/His. The amplicon expression plasmids
pHSV-EYFP-RfC_C.1 and pHSV-V5/His contain a transcription unit consisting of the HSV-1 immediate
early (IE) 4/5 promoter and the SV40 polyadenylation signal as well the HSV-1 origin of replication
(oriS) and the HSV-1 packaging/cleavage signal (pac) necessary for packaging into helper virus-free
HSV-1 amplicon particles. The HSV-1 amplicon vectors encoding single structural RV proteins
have been generated as follows: The single RV genes were amplified using the synthetic gene
expression cassettes (sWaRV) as the template. The resulting PCR product was inserted into pHSVS [47].
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The resulting HSV-1 amplicon plasmids encode for a single RV protein, sWaVP2, sWaVP6 or sWaVP7;
and after an IRES, the EGFP to identify vector-transduced cells.
4.3. Production of Herpes Simplex Virus Type-1 Amplicon Vector Stocks
Helper virus-free HSV-1 amplicon vector stocks were prepared as previously described [16,26].
Briefly, Vero 2-2 cells were co-transfected with amplicon plasmid DNA, the fHSV∆pac∆ICP27 BAC
DNA, and plasmid pEBHICP27 using Lipofectamine LTX and Plus Reagent (Thermo Fisher Scientific).
After 72 h, cells were scraped into the medium, freeze/thawed, sonicated, and the cell debris
was removed by centrifugation. For immunization of mice, vector stocks were further purified
and concentrated by centrifugation over a 25% sucrose cushion. For titration, Vero 2-2 cells were
infected with the amplicon vectors, and after 24 h stained for immune fluorescence using the
appropriate antibodies and fluorescent cells were counted using an inverted fluorescence microscope
(Axio Observer inverted microscope, Zeiss AG, Oberkochen, Germany). The titers were determined
as TU/mL.
4.4. Rotavirus-Like Particles Purification
HepG2 or Vero2-2 cells were transduced (MOI 2) with the indicated HSV-1 amplicon vector
and RVLPs were harvested 48 hpt as described previously [48,49]. Briefly, cells were scraped
into the medium and cell membranes were disrupted by repeated cycles of thawing/freezing.
The cell debris was removed by centrifugation at 1400× g and filtration through a 0.45 µm filter.
The cleared supernatant was loaded onto a 10% sucrose cushion and concentrated at 100,000× g for
2 h at 16 ◦C. For protection, protease inhibitor (protease inhibitor cocktail tablets complete, mini,
ethylenediaminetetraacetic acid (EDTA)-free, 1 tablet per 10 mL, Roche Diagnostics, Mannheim,
Germany) was added to the supernatant.
4.5. Western Blot Analysis
Cells were transduced with the indicated amplicon vectors (MOI 2) and total cell lysates were
harvested 24 hpt or 48 hpt if RVLPs were purified. Either whole cell lysates or sucrose purified RVLPs
(see section “RVLP purification”) were separated on 10% sodium dodecyl sulfate (SDS)-polyacrylamide
gels, transferred to nitrocellulose membranes, probed with primary antibodies, and stained using
anti-mouse (Sigma-Aldrich, Buchs, Switzerland) or anti-rabbit (Southern Biotech, Birmingham,
AL, USA) IgG antibodies conjugated with horseradish peroxidase (HRP), followed by detection
with WesternBright ECL spray (Advansta, Menlo Park, CA, USA) according to the manufacturer’s
instructions. Rabbit anti-rotavirus polyclonal serum raised against whole virus (1:4000, strain RF,
provided by Didier Poncet, The French National Center for Scientific Research (CNRS)/ National
Institute of Agricultural Research (INRA), Gif-sur-Yvette, France), guinea-pig anti-rotavirus polyclonal
serum raised against whole virus (1:2000, provided by Catherine Eichwald, University of Zurich,
Zurich, Switzerland), mouse anti-GFP monoclonal antibody (1:8000, JL-8, Santa Cruz, CA, USA),
mouse anti-V5 monoclonal antibody (1:5000, Molecular Probes, Thermo Fisher Scientific, Waltham,
MA, USA) and mouse anti-actin monoclonal antibody (1:10,000, Sigma–Aldrich) were used as primary
antibodies. For antibody stripping, membranes were incubated for 15 min with Stripping Buffer
(Thermo Scientific, Rockford, IL, USA) and washed three times with phosphate-buffered saline (PBS).
4.6. Immunofluorescence
Vero 2-2 cells were grown on 12 mm coverslips (0.17 mm thick) and transduced with the indicated
HSV-1 amplicon vector at the specified MOI. The cells were fixed 24 hpt with 3.7% formaldehyde in PBS
and treated with 0.1 M glycine in PBS. After permeabilization with PBS containing 0.2% Triton X-100
(PBS-T), the cells were blocked with PBS supplemented with 3% bovine serum albumin (PBS-BSA;
Sigma-Aldrich, Buchs, Switzerland). Cells were incubated with the corresponding antibodies diluted
in PBS-BSA: anti-VP2 antibody (1:200; provided by Didier Poncet, CNRS/INRA, Gif-sur-Yvette, France)
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directly labeled with Zenon Alexa-Fluor 594 according to the manufacturer’s instructions (Molecular
Probes, Thermo Fisher Scientific), mouse monoclonal anti-VP6 (1:500; Novus Biologicals, Cambridge,
UK) and the anti-mouse Alexa-Fluor 633 (1:500; Molecular Probes, Thermo Fisher Scientific), mouse
monoclonal anti-V5 antibody directly labeled with fluorescein isothiocyanate (FITC) (1:500; Molecular
Probes) for the V5-tagged VP7. The ER was stained using the Alexa-Fluor 405 conjugated lectin
ConA conjugated with Alexa Fluor 594 (20 µg/µL in PBS; Molecular Probes). Cells were incubated
with 4',6-diamidino-2-phenylindole (DAPI) (1 µg/mL in PBS, Roche, Basel, Switzerland) to visualize
nuclei. After washing the cells with PBS and H2O, the coverslips were mounted in ProLong Gold
(Molecular Probes). Samples were analyzed using a confocal laser-scanning microscope SP8 (Leica
Microsystems, Wetzlar, Germany, 63× oil objective (numerical aperture (NA) = 1.40)). For analysis of
RV protein-specific antibodies in the sera from immunized mice, sera was diluted 1:100 and detected
by staining with a secondary anti-mouse antibody conjugated with Alexa-Fluor 594 (1:500; Molecular
Probes). Pictures were taken using the fluorescence microscope (Axio Observer inverted microscope,
Carl Zeiss AG, Oberkochen, Germany).
4.7. Transmission Electron Microscopy
4.7.1. Negative Staining of Purified Rotavirus-Like Particles
For negative staining, samples (see section “RVLP purification”) were adsorbed to carbon-coated
parlodion films mounted on 300 mesh/inch copper grids (Electron Microscopy Sciences (EMS),
Fort Washington, PA, USA) for 10 min washed once with H2O, and stained with 2% phosphotungstic
acid (PTA), pH 7.0 (Aldrich, Steinheim, Germany) for 1 min. Specimens were analyzed in a transmission
electron microscope (CM12, Philips, Eindhoven, The Netherlands) equipped with a CCD camera
(Ultrascan 1000, Gatan, Pleasanton, CA, USA) at an acceleration voltage of 100 kV.
4.7.2. Immunogold Labeling of Purified Rotavirus-Like Particles
For immune electron microscopy, samples were adsorbed to carbon-coated parlodion films
mounted on 300 mesh/inch copper grids (EMS) for 10 min, blocked with PBS containing 0.1% BSA
(PBS-BSA/0.1%) for 10 min, incubated with the polyclonal rabbit anti-RV serum (strain RF, provided
by Didier Poncet, CNRS/INRA, Gif-sur-Yvette, France) at a dilution of 1:1000 PBS-BSA/0.1% for 1 h,
washed several times with PBS-BSA/0.1%, incubated with goat anti-rabbit IgG coupled to 12 nm
colloidal gold particles (Jackson ImmunoResearch, West Grove, PA, USA), washed several times with
PBS and H2O, and stained with 2% PTA, pH 7.0 (Aldrich) for 1 min. Specimens were analyzed in
a transmission electron microscope (CM12, Philips) equipped with a CCD camera (Ultrascan 1000,
Gatan) at an acceleration voltage of 100 keV.
4.7.3. Chemical Fixation and Embedding in Epon
HepG2 cells were transduced (MOI 5) with the HSV-1 amplicon vector sWa[VP2/6/7]. After 24 h,
the cells were scraped into the medium and resuspended in 2.5% glutaraldehyde (GA), centrifuged for
20 min at 4000 g and the pellet was embedded in Epon according to a standard protocol previously
described [50]. Briefly, the cell pellet was fixed with 2.5% GA and postfixed with 1% osmium tetroxide.
Before embedding in epoxy resin (Epon), the cell pellets were dehydrated through series of solvents.
Finally, ultrathin sections were stained with uranyl acetate and lead citrate and coated with carbon.
Specimens were analyzed in a transmission electron microscope (CM12, Philips) equipped with a CCD
camera (Orius SC1000W, Gatan) at an acceleration voltage of 100 keV.
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4.8. Correlative Light and Electron Microscopy
4.8.1. Chemical Fixation and Embedding in LR White
HepG2 cells were transduced (MOI 5) with the HSV-1 amplicon vector sWa[VP2/6/7_V5] and
24 hpt, the cells were scraped into the medium and centrifuged for 20 min at 4000× g. The resulting
cell pellet was fixed with 4% formaldehyde in 0.1 M Na/K phosphate buffer for 4 h. Thereafter, the
pellet was dehydrated with ascending ethanol series starting at 70%, followed by 80%, 96% and three
times in absolute ethanol for 10 min each. Next, the pellet was incubated at 4 ◦C for 1.5 h in a 2:1 mix
of LR White/Ethanol followed by infiltration of LR White (EMS) alone for 4 h and a final change of LR
White followed by overnight incubation at 4 ◦C. Embedding in LR white was done in gelatin capsules
at 50 ◦C for 24 h in an oven. Ultrathin sections were cut and collected on carbon-coated Formvar films
mounted on single slot copper grids (2 × 1 mm; EMS).
4.8.2. Immunofluorescence on Ultrathin Sections
The above described ultrathin sections of transduced HepG2 cells embedded in LR White
were incubated for 20 min with 50 mM Glycine before blocking for 30 min with blocking buffer
(0.5% BSA/0.1% gelatin (Cold Water Fish Skin, EMS, Hatfield, PA, USA)) followed by 5 min incubation
in 0.1% acetylated BSA (BSA-c) (Aurion, Wageningen, The Netherlands), pH 7.5 at room temperature
(RT). Incubation was done overnight with the polyclonal goat anti-RV serum (obtained from Catherine
Eichwald, University of Zurich, Zurich, Switzerland) diluted 1:10 in 0.1% BSA-c at 4 ◦C. After washing
five times with BSA-c, the sections were incubated with the secondary anti-goat antibody conjugated
with Alexa Fluor 488 (Molecular Probes), diluted 1:500 in 0.1% BSA-c for 1 h at RT. After washing
5 times with 0.1% BSA-c and once with H2O, the sections were stained with DAPI (0.1 mg/mL) for
15 min followed by 2 washes with PBS. After the staining, the sections were sandwiched between a
microscope slide and a coverslip in PBS and sealed with nail polish. With a fluorescence microscope
(Axio Observer inverted microscope), the whole grid was imaged in bright field and fluorescence and
several images were taken with a 100× oil (NA = 1.25) objective. These images served as maps and
were then used to find the same areas in the scanning electron microscope (SEM).
4.8.3. Scanning Electron Microscopy
The grids are recovered from the fluorescent microscope settings and further processed for electron
microscopy. The ultrathin sections were stained with uranyl acetate and lead citrate. Finally, the grids
are loaded into the scanning transmission electron microscope (STEM) holder of the SEM (Helios
NanoLab 650, FEI Company, Eindhoven, The Netherlands). The images taken with the fluorescence
microscope were opened on the SEM computer using the Maps software (FEI Company, Eindhoven,
The Netherlands), a specially designed software to correlate light and electron microscopy which
can read any type of images obtained by any type of light microscope. An electron micrograph was
recorded using the Everhart–Thorney secondary electron detector and the alignment between the light
and the electron micrograph was done using the Maps software using two auspicious points. A grid of
image tiles, tileset, was drawn over the area of interest, indicated by the fluorescence image. The tile
size was determined by the imaging conditions and had an overlap of 10%. Imaging conditions were:
30 keV, 1.6 nA, 5 mm working distance, 6144 × 4096 pixels per frame, 5 µm horizontal field of view
(about 8 Å pixel size), 1 µs dwell time using the STEM III detector (FEI Company) in the high-angle
annular-dark field mode. We used the three-point focus regime: at three points close to the area of
interest the section was focused at higher magnification, then brightness and contrast were adjusted
at the magnification and imaging conditions used for recording the images. Finally, the tiles were
stitched by the software and exported as tiff files. To circumvent any disturbing effects (e.g., bleaching),
occurring in the overlapping zones after stitching, the whole area of interest was pre-irradiated with a
high current (26 nA), large frame size (6144× 4096 pixels) and short dwell time (50 ns) for about 30 min.
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4.9. Immunization of Mice and Sample Collection
All animal procedures were conducted in accordance with the regulations of the Swiss Federal
Committee on Animal Experimentation and with the Veterinary Office of the Canton Zurich (approval
number: 70/2014). Six-to-eight-week-old naïve female BALB/c mice were i.m. inoculated at days 0
and for the first set of experiments at day 19 post-prime and for the second set of experiments 20 days
post-prime with either the indicated HSV-1 amplicon vectors (106 TU per animal per dose) or HBSS.
Five days after the prime immunization, mice were mated by adding one male to two females per cage.
Since multiple blood sampling was done regularly over a period of about two weeks, only small blood
samples (5–10 µL) were taken at each sampling via tail vein punctuation and collected using 20-µL
microcaps capillary tubes (Sigma–Aldrich). Mice were milked as described previously [50]. Briefly,
dams were separated from their offspring for about 2 h and then anesthetized. Oxytocin (100 µL of
10 IU/mL) was injected sub-cutaneous (s.c.) and milk flow was stimulated manually and collected
using microcaps capillary tubes.
4.10. Detection of Antibody Responses by Enzyme-Linked Immunosorbent Assay
Serum and milk IgG was analyzed by an indirect ELISA as described previously [50]. Briefly,
ELISA plates were coated with sucrose concentrated wt RV (strain Wa, diluted 1:100 in carbonate
buffer), washed with PBS-Tween (phosphate buffered saline with 0.05% Tween 20) and incubated
with the samples. Serum samples were diluted to 1:5000 and milk samples to 1:500 before application.
After washing with PBS-Tween, wells were incubated with the HRP-conjugated goat anti-mouse
IgG antibody (Pierce Biotechnologies, Rockford, IL, diluted 1:8000) and analyzed using peroxidase
substrate (TMB substrate solution, Thermo Scientific, Waltham, MA). Reaction was stopped with
2 M H2SO4 and the optical density was measured with an ELISA microplate reader. In order to
compare values from different ELISA plates, a serum pool of a RV hyper immunized mice from
previous studies [17] was used to normalize the values taking the hyper immune sera as 100%.
For the evaluation of IgG isotypes (IgG1, IgG2a and IgG2b) standardized biotinylated isotype-specific
monoclonal antibodies (IgG1: RMG1-1, 0.1 µg/mL, IgG2a: RMG2a-62, 0.2 µg/mL, IgG2b: RMG2b-1,
1.6 µg/mL, all from BioLegend, San Diego, CA, USA) and for detection HRP-conjugated streptavidin
(1:2000, BioLegend, San Diego, CA, USA) were used. For the standardization IgG1; IgG2a; IgG2b
monoclonal immunoglobulins were first coated in identical concentrations directly to ELISA plates
as antigen, followed by various dilutions of the detection system and appropriate concentrations of
the antibodies (given above) selected. Serum samples of dams and their pups (diluted 1:1000) were
reanalyzed with the antigen coated as above but the IgG isotypes were detected with the appropriate
standardized detection system.
4.11. Virus Challenge of Newborns
Rotavirus challenge of 2- to 4-days-old suckling mice from all groups was performed by oral
gavage of 30 µL of virus-containing solution (strain EDIM, 10× DD50) using a feeding needle. Pups
were monitored twice a day for RV symptoms (diarrhea and dehydration) as well as for overall
physical appearance. They were considered sick when yellow and liquid stools appeared upon gentle
abdominal palpation.
4.12. Reverse Transcription Quantitative Real-Time Polymerase Chain Reaction
Quantitative real-time polymerase chain reaction (RT-qPCR) was performed directly from serum
samples. The serum samples were 1:5 diluted in 1× PBS and heated for 3 min at 97 ◦C, cooled immediately
on wet ice for 5 min and used directly for the RT-qPCR reaction. The Path-ID Multiplex One-Step
RT-PCR Kit (Applied Biosystems, Thermo Fisher Scientific) was used for the amplification. As
primer probe, we used the VetMax Swine Enteric Panel Reagent (Applied Biosystems, Thermo Fisher
Scientific), a primer probe mix for detection of porcine rotavirus A—besides a primer probe for porcine
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rotavirus A, this kit contains also primer probes for transmissible gastroenteritis coronavirus (TGEV)
and porcine epidemic diarrhea virus (PEDV)—. This primer probe mix was selected because it was the
most sensitive kit. The reaction was run in a thermal cycler (CFX96 C1000 Touch, BioRad, Hercules,
CA, USA) using the following settings: reverse transcription for 10 min at 48 ◦C followed by an
inactivation/initial denaturation step of 10 min at 95 ◦C. Amplification was performed as 40 cycles
of 15 s at 95 ◦C and 45 s at 60 ◦C. Reactions were done in duplicates. For calculation of virus dose,
a standard curve was drawn using serial dilution of EDIM virus diluted in negative mouse serum and
treated as described above in triplicates. Based on the resulting formula of the determined standard
curve (ln(DD50) = −0.6419 × Cq + 16.565), DD50 was calculated for each sample. Considering the
applied volume of the analyzed samples, DD50/mL was determined (DD50/0.0016 mL).
4.13. Statistical Analysis
Enzyme-linked immunosorbent assay measurements were analyzed as follows: The mean of
each sample triplicate was calculated and the mean value of the negative control from the same plate
was subtracted. To make values between the plates comparable, always the same positive control
was applied on each plate. The mean of each sample triplicate was then set in relation to the mean
of the positive control (100%) from the individual plate. A two-way ANOVA with weighted means
was performed to calculate the p-values. For samples of Figure 3D, Tukey ad hoc testing was done to
determine the p-values between all groups. Pre-processing of data (normalization, calculation of means
and standard deviations) was performed with Microsoft Excel 2011 (Version 14.1.0). Two-way ANOVA
with weighted means and Tukey ad hoc testing were performed using the open source program
RStudio (Version 0.99.903—2009–2016 RStudio, Inc., Boston, MA, USA). Graphs were generated
with RStudio.
5. Conclusions
The main aim of this study was to evaluate a safe RV-specific vaccine based on the non-replicating
HSV-1 amplicon vector system to induce protective systemic antibodies in a first attempt. For this,
the RV proteins were used in a structural vaccinology approach. The transduction with the RV
protein encoding HSV-1 amplicon vector sWa[VP2/6/7] triggered the synthesis of all three encoded
RV proteins, VP2, VP6 and VP7, as well as the intracellular assembly of RVLPs in cell culture.
The distribution of the viral proteins within the cell resembled the localization of proteins in wild
type RV infections. When administered intramuscularly, the RV proteins encoding HSV-1 amplicon
vectors induced a strong RV specific antibody response in sera as well as in milk of vaccinated dams.
In addition, the antibody response was passed through both the placental and/or lactogenic route to
unvaccinated offspring swapped to vaccinated dams. As expected, lactogenic transfer of RV specific
IgG did not protect the suckling mice from developing RV symptoms upon challenge. Indications
of control of systemic spread were noted but will require more targeted experiments. Although full
protection against an oral RV challenge was not achieved and would require both oral and systemic
vaccination, the helpervirus-free herpesvirus amplicon vectors used in this study may be rapidly
adapted to confer immunity against a whole array of different RVs.
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Figure A1. Analysis of guinea pig anti-RV serum specificity. Western blot analysis of whole HepG2 
cell lysates from sWa[VP2/6/7] or GFP amplicon vector transduced (MOI 2) or non-transduced mock 
cells. Proteins were analyzed using the guinea pig polyclonal anti-RV antibody (upper panel);  
anti-actin antibody (middle panel); or the anti-GFP antibody (lower panel). Expected migration 
lengths of the RV proteins VP2 and VP6, actin and GFP are indicated on the left with arrows and the 
positions of the molecular weight markers are shown on the right in kDa.  
Table A1. This table shows all data used to generate Figure 3B as well as the number of animals 
included in this study and the p-values.  
Group dpb rIgG (%) SD No. Animals p-Value 1 
sWa[VP2/6/7] −19 1.449 1.213 6 
0.3025 GFP −19 0.693 0.227 4 
sWa[VP2/6/7] 0 3.570 0.730 6 
1.40 × 10−5 GFP 0 0.846 0.264 6 
sWa[VP2/6/7] 10 54.852 13.770 7 
0.002028 GFP 10 2.147 0.311 2 
sWa[VP2/6/7] 14 37.893 11.319 6 0.00011 GFP 14 1.383 0.775 5 
sWa[VP2/6/7] 20 23.777 8.309 2 0.03876 GFP 20 1.916 0.338 3 
1 p-values were calculated applying a two-way ANOVA. Measurements from sWa[VP2/6/7]-
immunized versus GFP-immunized animals are compared. dpb: Days post-booster immunization; 
rIgG: Relative RV specific IgG; SD: Standard deviation. 
  
Figure A1. Analysis of guinea pig anti-RV serum specificity. Western blot analysis of whole HepG2 cell
lysates from sWa[VP2/6/7] or GFP amplicon vector transduced (MOI 2) or non-transduced mock cells.
Proteins were analyzed using the guinea pig polyclonal anti-RV antibody (upper panel); anti-actin
antibody (middle panel); or the anti-GFP antibody (lower panel). Expected migration lengths of the RV
proteins VP2 and VP6, actin and GFP are indicated on the left with arrows and the positions of the
molecular weight markers are shown on the right in kDa.
Table A1. This table shows al data rate Figure 3B as well as the number of animals
included in this tudy and the p-values.
Group dpb rIgG (%) SD No. Animals p-Value 1
sWa[VP2/6/7] −19 1.449 1.213 6
0.3025GFP −19 0.693 0.227 4
sWa[VP2/6/7] 0 3.570 0.730 6
1.40 × 10−5GFP 0 0.846 0.264 6
sWa[VP2/6/7] 10 54.852 13.770 7
0.002028GFP 10 2.147 0.311 2
sWa[VP2/6/7] 14 37.893 11.319 6
0.00011GFP 14 1.383 0.775 5
sWa[VP2/6/7] 20 23.777 8.309 2
0.03876GFP 20 1.916 0.338 3
1 p-values were calculated applying a two-way ANOVA. Measurements from sWa[VP2/6/7]-immunized versus
GFP-i munized animals are co pared. dpb: Days post-boost r immuniz tion; rIgG: Relative RV specific IgG;
SD: Standard deviation.
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Table A2. This table displays all data used to generate Figure 3C as well as the number of animals
included in this study and the p-values.
Group dpd rIgG SD No. Animals p-Value 1
GFP 0 1.774 1.044 3
0.008351sWa[VP2/6/7] 0 42.567 14.131 4
GFP 3 2.289 0.612 3
1.58 × 10−5sWa[VP2/6/7] 3 57.135 6.547 5
GFP 6 1.800 0.210 3
0.001049sWa[VP2/6/7] 6 50.328 12.327 5
1 p-values were calculated with a two-way ANOVA comparing the measurements from sWa[VP2/6/7]-immunized
versus GFP-immunized animals.
Table A3. This table displays all data used to generate Figure 3D as well as the number of animals
included in this study and the p-values.
Group dpd rIgG SD No. Animals p-Value 1
GFP 0 1.236 0.509 3
0.001761sWa[VP2/6/7] 0 46.640 10.952 4
GFP 3 2.253 0.659 3
0.001214sWa[VP2/6/7] 3 57.263 14.364 5
GFP 6 1.966 0.565 3
0.004806sWa[VP2/6/7] 6 51.828 17.176 5
1 p-values were calculated with a two-way ANOVA comparing the measurements from sWa[VP2/6/7]-immunized
versus GFP-immunized animals.
Table A4. Optical density values of IgG isotype ELISA from serum samples (diluted 1:1000) of
sWaRV[VP2/6/7] or GFP control immunized animals.
Group Animal IgG1 IgG2a IgG2b
sWaRV[VP2/6/7] Dam 1 0.072 0.274 0.077
sWaRV[VP2/6/7] Pups Dam 1 0.104 0.389 0.042
sWaRV[VP2/6/7] Dam 2 0.086 0.122 0.018
sWaRV[VP2/6/7] Pups Dam 2 0.201 0.367 0.033
sWaRV[VP2/6/7] Dam 3 0.086 0.337 0.014
sWaRV[VP2/6/7] Pups Dam 3 0.163 0.612 0.013
sWaRV[VP2/6/7] Dam 4 0.035 0.114 0.011
sWaRV[VP2/6/7] Pups Dam 4 0.075 0.370 0.010
GFP Dam 5 0.016 0.026 0.009
GFP Pups Dam 5 0.017 0.020 0.014
GFP Dam 6 0.024 0.018 0.013
GFP Pups Dam 6 0.033 0.025 0.012
GFP Dam 7 0.0096 0.014 0.010
GFP Dam 8 0.037 0.029 0.012
GFP Pups Dam 7/8 0.030 0.045 0.010
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Table A5. Ratio of IgG isotype values from sWaRV[VP2/6/7] immunized animals from Table A10.
Group Animal IgG1/IgG2a IgG1/IgG2b
sWaRV[VP2/6/7] Dam 1 0.263 0.934
sWaRV[VP2/6/7] Pups Dam 1 0.267 2.491
sWaRV[VP2/6/7] Dam 2 0.707 4.803
sWaRV[VP2/6/7] Pups Dam 2 0.549 6.110
sWaRV[VP2/6/7] Dam 3 0.256 5.977
sWaRV[VP2/6/7] Pups Dam 3 0.266 12.253
sWaRV[VP2/6/7] Dam 4 0.305 3.229
sWaRV[VP2/6/7] Pups Dam 4 0.203 7.426
Table A6. This table shows the relative IgG values of serum samples of the dams from experiment 2.
These dams raised the pups further analyzed in Figure 3E.
Group dpb rIgG (%) SD No. Animals
GFP −20 1.327 0.163 6
GFP 0 1.899 0.419 6
GFP 8 4.144 0.684 6
GFP 11 2.786 0.552 2
GFP 12 3.361 0.685 4
HBSS −20 0.741 0.682 10
HBSS 0 0.448 0.409 8
HBSS 5 0.705 0.518 2
HBSS 6 0.610 0.573 3
HBSS 9 0.242 0.149 3
HBSS 11 2.224 1.822 2
HBSS 12 1.751 1.036 3
HBSS 15 1.171 1.306 3
sWa[VP2/6/7] −20 0.816 0.639 6
sWa[VP2/6/7] 0 4.452 2.633 6
sWa[VP2/6/7] 7 32.853 0.000 1
sWa[VP2/6/7] 8 37.313 5.621 3
sWa[VP2/6/7] 9 40.592 0.534 2
sWa[VP2/6/7] 11 46.500 0.000 1
sWa[VP2/6/7] 14 29.957 2.138 3
sWa[VP2/6/7] 15 33.809 1.109 2
Table A7. This table shows the relative IgG values of milk samples of the dams from experiment 2.
These dams raised the pups further analyzed in Figure 3E.
Group dpb rIgG (%) SD No. Animals
GFP 0 61.600 1.661 2
GFP 2 52.830 10.911 2
HBSS 0 0.575 0.141 4
HBSS 1 0.279 0.051 4
HBSS 2 0.263 0.120 2
HBSS 6 0.431 0.128 2
HBSS 7 0.378 0.129 3
HBSS 8 0.271 0.000 1
sWaRV2/6/7 1 57.312 8.009 5
sWaRV2/6/7 2 40.092 0.336 2
sWaRV2/6/7 6 42.919 0.000 1
sWaRV2/6/7 7 39.086 6.285 4
sWaRV2/6/7 8 31.470 0.000 1
GFP 0 61.600 1.661 2
GFP 2 52.830 10.911 2
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Table A8. This table shows all data used to generate Figure 3E as well as the number of animals included
in the study. p-values are shown in Table A7A.
Group rIgG SD No. Animals
A 21.103 4.023 4
B 25.386 6.109 6
C 4.421 1.032 8
D 0.465 0.426 13
E 2.461 0.441 31
Table A9. This table shows the p-values between the indicated groups from the data used for Figure 3E
and the data displayed in Table A6.
Compared Groups p-Value 1
B-A 0.5688202
C-A 0.0006268
D-A 0.0000157
E-A 0.0000537
C-B 0.0000129
D-B 0.0000002
E-B 0.0000006
D-C 0.6376254
E-C 0.9552024
E-D 0.9224124
1 p-values were calculated using the Tukey ad hoc test.
Table A10. This table shows the quantification cycle (Cq) values of pooled serum samples of pups
analyzed by RV-specific RT-qPCR.
Group Cq 1 Cq 2 Cq 3 Cq 4 Mean Cq DD50/mL
A: Pups born and raised by
sWa[VP2/6/7]-immunized dams - - 38.235 36.055 37.145 4.314
B: Pups born from HBSS-injected
dams but raised by
sWa[VP2/6/7]-immunized dams
29.28 34.81 33.39 30.41 31.973 119.365
C: Pups born from
sWa[VP2/6/7]-immunized dams and
raised by HBSS-injected control dams
- 33.77 31.11 28.445 31.108 207.867
DD50: Diarrhea dose 50.
Table A11. This table summarizes the data and variables obtained during the challenge experiment
shown in Figure 3E.
Group LitterSize
Pup Age at
Challenge (Days)
Time until
Diarrhea (Days)
Pup Age at
Sampling (Days)
Mean Cq from
Triplicates DD50 DD50/mL
A 3 4 2.5 6.5 38.235 0.003 2.143
A 3 3 2 5 36.055 0.014 8.685
B 4 4 2 6 29.280 1.075 672.166
B 4 4 2.5 6.5 34.810 0.031 19.313
B 3 5 2 7 33.390 0.077 48.053
B 4 4 2 6 30.410 0.521 325.433
C 4 4 2.5 6.5 33.770 0.060 37.652
C 6 4 2 6 31.110 0.332 207.645
C 5 5 2 7 28.445 1.838 1148.821
D 6 4 1.5 5.5 33.880 0.056 35.085
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Table A11. Cont.
Group LitterSize
Pup Age at
Challenge (Days)
Time until
Diarrhea (Days)
Pup Age at
Sampling (Days)
Mean Cq from
Triplicates DD50 DD50/mL
D 7 4 1.5 5.5 31.770 0.217 135.935
D 3 3 2.5 5.5 36.200 0.013 7.913
D 4 3 2 5 35.590 0.019 11.706
D 6 4 1.5 5.5 30.950 0.368 230.104
E 8 2 2 4 34.430 0.039 24.649
E 8 2 2.5 4.5 35.405 0.021 13.182
E 4 3 2 5 34.885 0.029 18.406
E 5 3 2.5 5.5 32.680 0.121 75.796
E 6 4 2.5 6.5 32.520 0.134 83.994
Group A: Offspring born and raised by sWa[VP2/6/7]-immunized dams; Group B: Offspring born
from HBSS-injected dams but raised by sWa[VP2/6/7]-immunized dams; Group C: Offspring born from
sWa[VP2/6/7]-immunized dams and raised by HBSS-injected control dams; Group D: Offspring born and raised by
HBSS-injected control animals; Group E: Offspring born and raised by GFP vector-immunized dams.
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